A Phase 4 interventional study of Everolimus (RAD001) in Metastatic Renal Cell Carcinoma (mRCC), sponsored by Novartis Pharmaceuticals. Completed at 13 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies testing everolimus in Carcinoma, Renal Cell — 4 open to participants now, 7 under way, 2 of them phase 3. Everolimus · Carcinoma, Renal Cell.
Among the 48 studies testing everolimus in Carcinoma, Renal Cell, this one is the 33rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 4, and was the 31st registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →4 of the 48 studies testing everolimus in Carcinoma, Renal Cell are open now, in 2 countries. Recruiting first, the newest first:
Kidney Cancer Research Bureau · Sites in Russia
Ages 18 mo+
Peking University First Hospital · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Peking University Cancer Hospital & Institute · Sites in China
Ages 18–80
By country, each count listing its studies:
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 28 · Phase 3 4 · Phase 4 5
First in 2004; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 43 across 1,565 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 46 across the 48 interventional studies. Of the 40 that completed or were terminated, 20 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 48 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
38 studies in Carcinoma, Renal Cell by Novartis: none open now, 1 under way, none of them phase 3. Of 36 finished, 17 (47%) have results posted.
Among the 38 studies in Carcinoma, Renal Cell by Novartis, this one is the 32nd largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 4, and was the 23rd registered.
Novartis’s Carcinoma, Renal Cell studies by the year they started, since 2001.
2 of the studies testing everolimus in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07937553Kidney Cancer Research BureauCombinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. | 2027-08-01 |
| NCT05012371M.D. Anderson Cancer CenterLenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | 2027-10-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 48 studies testing everolimus in Carcinoma, Renal Cell, from their registry updates:
Among Novartis’s 38 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
Drug: Everolimus (RAD001)
Everolimus was used as commercially available formulated tablets of 10 mg strength
Also known as: RAD001
Percentage of Progression-free Patients by Month 6
Percentage of progression-free patients by month 6 after starting everolimus treatment. For the purpose of the binomial design of the study, a patient being 'progression-free' will be defined as a patient without disease progression by month 6 whereas a subject with progressive disease by month 6 will not be counted as 'progression-free'. The primary variable was derived from radiologic tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) Disease progression was either 1) a 20% increase in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameters of all target lesions recorded at or after baseline (minimum absolute increase 5 mm in sum) or 2) the appearance of a new lesion or 3) the unequivocal progression of non-target lesions overall.
Time frame: Month 6
Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6
Overall response rate (ORR) is the Percentage of patients with a best overall response of complete response (CR) or partial response (PR) by month 6. ORR was assessed according to RECIST 1.1 criteria. Partial response (PR) required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as reference the baseline sum of the longest diameters. Complete response (CR) required a disappearance of all target and non-target lesions.
Time frame: Month 6
Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment
Time frame: 24 months
Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months
Overall survival (OS) was defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival will be censored at the date of last contact.
Time frame: 48 months
Duration of Response (DOR) in Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months
The duration of overall response (DOR) was defined as the time from the first occurrence of a confirmed Complete Response (CR) or Partial Response (PR) (as per investigator assessment according to RECIST 1.1) until the date of the first documented disease progression or death due to underlying cancer. If a patient did not have an event or received any further anticancer therapy, duration of overall response was censored at the date of last adequate tumor assessment. Duration of response was displayed only for patients whose best overall response was CR or PR. As none of the patients showed any response (CR or PR), DOR could not be calculated
Time frame: 48 months
| Milestone | 1st Line SUN | 1st Line PAZ |
|---|---|---|
| Started | 16 | 13 |
| Full analysis set (fas) | 12 | 13 |
| Completed | 4 | 5 |
| Not completed | 12 | 8 |
| Withdrew: Death | 7 | 8 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: New cancer therapy | 1 | 0 |
Percentage of progression-free patients by month 6 after starting everolimus treatment. For the purpose of the binomial design of the study, a patient being 'progression-free' will be defined as a patient without disease progression by month 6 whereas a subject with progressive disease by month 6 will not be counted as 'progression-free'. The primary variable was derived from radiologic tumor assessments according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1.) Disease progression was either 1) a 20% increase in the sum of the longest diameter of all target lesions, taking as reference the smallest sum of the longest diameters of all target lesions recorded at or after baseline (minimum absolute increase 5 mm in sum) or 2) the appearance of a new lesion or 3) the unequivocal progression of non-target lesions overall.
| Percentage of participants | 1st Line SUN | 1st Line PAZ |
|---|---|---|
| Percentage of Progression-free Patients by Month 6 | 8.3 | 46.2 |
Overall response rate (ORR) is the Percentage of patients with a best overall response of complete response (CR) or partial response (PR) by month 6. ORR was assessed according to RECIST 1.1 criteria. Partial response (PR) required at least a 30% decrease in the sum of the longest diameters of all target lesions, taking as reference the baseline sum of the longest diameters. Complete response (CR) required a disappearance of all target and non-target lesions.
| percentage of participants | 1st Line SUN | 1st Line PAZ |
|---|---|---|
| Percentage of Patients With Overall Response Rate (ORR) Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy at Month 6 | 0.0 | 0.0 |
Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient did not have an event, progression-free survival was censored at the date of last adequate tumor assessment
| months | 1st Line SUN | 1st Line PAZ |
|---|---|---|
| Progression-Free Survival (PFS) as the Time Interval Between First Intake of Everolimus and First Documented Disease Progression or Death Due to Any Cause at 24 Months | 2.8 (2.6 to 3.1) | 8.0 (3.0 to 10.3) |
Overall survival (OS) was defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival will be censored at the date of last contact.
| months | 1st Line SUN | 1st Line PAZ |
|---|---|---|
| Overall Survival (OS) of Patients Treated With Everolimus After Failure of First-line Sunitinib or Pazopanib Therapy up to 48 Months | 14.8 (10.0 to NA) | 20.4 (13.6 to NA) |
The duration of overall response (DOR) was defined as the time from the first occurrence of a confirmed Complete Response (CR) or Partial Response (PR) (as per investigator assessment according to RECIST 1.1) until the date of the first documented disease progression or death due to underlying cancer. If a patient did not have an event or received any further anticancer therapy, duration of overall response was censored at the date of last adequate tumor assessment. Duration of response was displayed only for patients whose best overall response was CR or PR. As none of the patients showed any response (CR or PR), DOR could not be calculated
No measurements were reported for this outcome.
Collected over Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1st Line SUN | — | 6/16 (37.5%) | 15/16 (93.8%) |
| 1st Line PAZ | — | 8/13 (61.5%) | 13/13 (100%) |
| Everolimus All Patients | — | 14/29 (48.3%) | 28/29 (96.6%) |
| Event | 1st Line SUN | 1st Line PAZ | Everolimus All Patients |
|---|---|---|---|
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 1/16 | 3/13 | 4/29 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 0/16 | 2/13 | 2/29 |
| ANAEMIABlood and lymphatic system disorders | 1/16 | 1/13 | 2/29 |
| ATRIOVENTRICULAR BLOCK COMPLETECardiac disorders | 0/16 | 1/13 | 1/29 |
| ABDOMINAL PAINGastrointestinal disorders | 0/16 | 1/13 | 1/29 |
| HAEMORRHOIDSGastrointestinal disorders | 0/16 | 1/13 | 1/29 |
| STOMATITISGastrointestinal disorders | 0/16 | 1/13 | 1/29 |
| ASTHENIAGeneral disorders | 0/16 | 1/13 | 1/29 |
| GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders | 1/16 | 1/13 | 2/29 |
| ENDOCARDITISInfections and infestations | 1/16 | 1/13 | 2/29 |
| Event | 1st Line SUN | 1st Line PAZ | Everolimus All Patients |
|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 4/16 | 7/13 | 11/29 |
| STOMATITISGastrointestinal disorders | 2/16 | 7/13 | 9/29 |
| FATIGUEGeneral disorders | 5/16 | 7/13 | 12/29 |
| OEDEMA PERIPHERALGeneral disorders | 2/16 | 7/13 | 9/29 |
| NAUSEAGastrointestinal disorders | 3/16 | 6/13 | 9/29 |
| DECREASED APPETITEMetabolism and nutrition disorders | 5/16 | 5/13 | 10/29 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/16 | 5/13 | 11/29 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/16 | 5/13 | 7/29 |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 2/16 | 5/13 | 7/29 |
| PRURITUSSkin and subcutaneous tissue disorders | 3/16 | 5/13 | 8/29 |
Demographic and other baseline data (including disease characteristics) were summarized descriptively for all patients for the FAS. The full analysis set (FAS) consisted of all patients who received at least one dose of everolimus.
| Age, Continuous(years) | 1st Line SUN | 1st Line PAZ | Total |
|---|---|---|---|
| Mean | 67.6 ± 6.3 | 71.3 ± 6.0 | 69.2 ± 6.3 |
| Sex: Female, Male(Participants) | 1st Line SUN | 1st Line PAZ | Total |
|---|---|---|---|
| Female | 6 | 2 | 8 |
| Male | 6 | 11 | 17 |
Ran from May 2012 to primary completion in Apr 2016, 46 months.
Results were first posted in Jul 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus